• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

1.170 -0.110 (-8.59%)
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,657
Open 1.280
Bid (Size) 1.120 (1,000)
Ask (Size) 1.250 (100)
Prev. Close 1.280
Today's Range 1.170 - 1.280
52wk Range 1.120 - 4.700
Shares Outstanding 3,192,040
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
October 15, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
September 29, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire

Performance

52-Week Range 75.1% below 52-week high
1.170
1.1252W Low 4.7052W High
1 Week 12.0% below 1-week high
1.121W Low 1.331W High

Cellectar Biosciences, Inc. - Common Stock (CLRB) traded between $1.12 and $4.70 over the past 52 weeks and last traded at $1.17, 75.1% below its 52-week high. Over the past week it ranged between $1.12 and $1.33.

Past 12 Months
+2.6%
-47.5%
-52.6%
-58.0%
-66.3%
-70.2%
1W +$0.03
1M -$1.06
3M -$1.30
6M -$1.62
YTD -$2.30
1Y -$2.75

CLRB was -70.2% over the past year, -58.0% over six months, -66.3% year to date, +2.6% in the last week.

12 Months vs Market
CLRB
-70.2%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%

Over the past 12 months CLRB returned -70.2% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.84× 3-mo avg
Today 68,657 3-mo avg 81.9K
1W
169.9K
1M
158.0K
3M
81.9K
6M
562.9K
YTD
374.7K
1Y
334.0K

CLRB most recently traded 68,657 shares against a 3-month average daily volume of 81.9K.

More News

Read More
News headline image
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript ↗
August 20, 2026
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For November 13, 2025 ↗
November 13, 2025
Via Benzinga
News headline image
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 13, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
July 30, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
July 15, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
June 01, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar (CLRB) Q1 2026 Earnings Transcript ↗
May 14, 2026
Via The Motley Fool
News headline image
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 14, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
May 11, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
May 05, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
May 05, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
April 21, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
April 14, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar (CLRB) Q4 2025 Earnings Call Transcript ↗
March 04, 2026
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
March 04, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
February 25, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Expands Global Intellectual Property Estate
February 17, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
January 09, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
December 16, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Outlook For Cellectar Biosciences ↗
November 12, 2025
Via Benzinga
News headline image
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
November 06, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
October 27, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cellectar Biosciences, Inc. - Common Stock publicly traded?
Yes, Cellectar Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Cellectar Biosciences, Inc. - Common Stock trade on?
Cellectar Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cellectar Biosciences, Inc. - Common Stock?
The ticker symbol for Cellectar Biosciences, Inc. - Common Stock is CLRB on the Nasdaq Stock Market
What is the current price of Cellectar Biosciences, Inc. - Common Stock?
The current price of Cellectar Biosciences, Inc. - Common Stock is 1.170
When was Cellectar Biosciences, Inc. - Common Stock last traded?
The last trade of Cellectar Biosciences, Inc. - Common Stock was at 10/22/26 04:00 PM ET
What is the market capitalization of Cellectar Biosciences, Inc. - Common Stock?
The market capitalization of Cellectar Biosciences, Inc. - Common Stock is 3.73M
How many shares of Cellectar Biosciences, Inc. - Common Stock are outstanding?
Cellectar Biosciences, Inc. - Common Stock has 4M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap